ArticleScientific reports2025
Skin microbiome friendly topical formulations containing probiotic - loaded alginate microspheres: in vitro studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Probiotic-Mediated Inhibition of Skin Pathogens and Modulation of Innate Immune Responses in HaCaT Cells.Microorganisms · 2026Article
- Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches.Molecules (Basel, Switzerland) · 2026Review
- Modulation of Caffeine Permeation Kinetics in a Skin-PAMPA Model by Probiotic Lysates and Bile Acids.Pharmaceutics · 2026Article
- Cosmetic Interventions for Skin Microbiome Modulation: Current Strategies and Future Directions.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026Review
- Article
- Skin microbiome and cutaneous aging mechanisms and clinical implications.Frontiers in microbiology · 2026Review
- Ex vivo Evaluation of Live-MB2 and CX-2 Biotic Strains on Inflammatory and Barrier-Related Biomarkers in a Human Skin Atopic Dermatitis-Like Model.Clinical, cosmetic and investigational dermatology · 2026Article
- The skin microbiome: from historical ecology to therapeutic frontiers.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin dysbiosis—a perturbed microbiome balance—is associated with numerous skin conditions. To manage dysbiosis, pre- and probiotics may be used as modulators to restore microbial balance. In this study, Lactobacillus casei ATCC 393-based novel probiotic formulation has been elaborated. The antimicrobial activity of L. casei against Staphylococcus epidermidis and Staphylococcus aureus was studied using kill test and well diffusion assay. The probiotic strain was found to be active against S. aureus (0.81 and 0.99 log reduction of S. aureus cells after 5 and 24 h, respectively). The well diffusion assay showed that L. casei metabolites were active against S. aureus (zone of inhibition: 5 mm). Alginate-prebiotic (tapioca flour)-encapsulated probiotic strain microspheres were used as active ingredients in a topical formulation. The safety and efficacy of this formulation was determined in vitro in human keratinocytes (HaCaT) and fibroblasts (HSF), analyzing cytotoxicity, cell proliferation rate, and proinflammatory cytokine (IL-6 and IL-8) release. In addition, the formulation+n exhibited regenerative potential in the scratch test. In vitro studies showed that the formulation containing MP reduced the survival of pathogenic strains (E. coli, S. aureus, C. albicans, C. neoformans) compared to the base formulation, devoid of lactic acid bacteria (even by 2.82 log).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.